Efficacy and Safety of the Combination of Transarterial Chemoembolization with Camrelizumab plus Apatinib for Advanced Hepatocellular Carcinoma: A Retrospective Study of 38 Patients from a Single Center

<table class="table-group" id="tab2"><tr><td><table class="table"><tr><td class="thead-hr" colspan="2"><hr/></td></tr><tr class="thead"><td class="align_left">Tumor response</td><td class="align_center"><i>n</i> (%)</td></tr><tr><td class="thead-hr" colspan="2"><hr/></td></tr><tr><td class="align_left">Complete response</td><td class="align_center">1 (2.6)</td></tr><tr><td class="align_left">Partial response</td><td class="align_center">18 (47.4)</td></tr><tr><td class="align_left">Stable disease</td><td class="align_center">19 (26.3)</td></tr><tr><td class="align_left">Progressive disease</td><td class="align_center">9 (23.7)</td></tr><tr><td class="align_left">Objective response rate</td><td class="align_center">19/38 (50.0)</td></tr><tr><td class="align_left">Disease control rate</td><td class="align_center">29/38 (76.3)</td></tr><tr class="table-tr"><td colspan="2"><hr class="tbody-hr"/></td></tr></table></td></tr></table>

<div>Response to combined therapy (<i>n</i> = 38).</div>

Canadian Journal of Gastroenterology and Hepatology

tab2

Table 2

Table 2: Efficacy and Safety of the Combination of Transarterial Chemoembolization with Camrelizumab plus Apatinib for Advanced Hepatocellular Carcinoma: A Retrospective Study of 38 Patients from a Single Center 

Table 2 | Efficacy and Safety of the Combination of Transarterial Chemoembolization with Camrelizumab plus Apatinib for Advanced Hepatocellular Carcinoma: A Retrospective Study of 38 Patients from a Single Center 